Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation.

Author: BechsteinW O, BergT, MüllerA R, NeuhausP, NeuhausR, RayesN, SeehoferD

Paper Details 
Original Abstract of the Article :
Since the introduction of famciclovir in the treatment of hepatitis B virus (HBV) infection after liver transplantation, promising results have been published. In this study, the long-term efficacy and safety of famciclovir were assessed. Twenty-four patients with recurrent hepatitis B and 6 patient...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1034/j.1399-0012.1999.130602.x

データ提供:米国国立医学図書館(NLM)

Famciclovir: A Temporary Oasis in the Desert of Hepatitis B

The field of [hepatitis B virus (HBV) infection] is fraught with challenges, particularly in the context of [liver transplantation], where the risk of [reinfection] is a significant concern. This study investigates the efficacy and safety of [famciclovir] in treating [recurrent or de novo HBV infection] after [liver transplantation], offering hope for patients in this challenging situation.

The study found that [famciclovir] was effective in reducing [HBV-DNA] levels in a majority of patients, leading to [viral suppression] for a period of time. However, the researchers also observed [viral breakthrough] in many patients, with [HBV-DNA] levels rising again after a period of suppression. This suggests that [famciclovir] may provide a temporary respite but may not offer a long-term solution for [HBV infection] in this setting.

Despite the [viral breakthrough] observed in many patients, [famciclovir] was well-tolerated and did not cause any significant [adverse effects]. This indicates that [famciclovir] may be a valuable tool for managing [HBV infection] in the short term, but further research is needed to develop more durable treatment strategies.

Famciclovir: A Bridge in the Sandstorm of HBV Infection

While [famciclovir] may not be the ultimate solution for [HBV infection] after [liver transplantation], it offers a temporary bridge across the turbulent sandstorm of viral replication. It provides a valuable tool for managing the infection, allowing for time to explore other treatment options and develop more durable strategies. This research highlights the ever-changing landscape of [HBV infection] and the ongoing quest for effective and sustainable treatments.

Dr.Camel's Conclusion

The desert of [HBV infection] is a challenging terrain, and [famciclovir] offers a temporary oasis of respite for patients after [liver transplantation]. While it may not offer a permanent solution, it provides a valuable opportunity to manage the infection and explore new approaches. The quest for sustainable treatments continues, and this research serves as a reminder that even in the most barren of medical landscapes, there's always hope for finding a source of relief.

Date :
  1. Date Completed 2000-01-19
  2. Date Revised 2019-11-03
Further Info :

Pubmed ID

10617232

DOI: Digital Object Identifier

10.1034/j.1399-0012.1999.130602.x

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.